Gábor Varró, Éva Bozó, Krisztina Vukics, Ferenc Baska, Gábor Szántó, Balázs Krámos, Katalin Domány-Kovács, Krisztina Szondiné Kordás, Mónika Vastag, Ildikó Magdó, Imre Bata
{"title":"Development of dual V1a/V2 antagonists containing triazolobenzazepine scaffold","authors":"Gábor Varró, Éva Bozó, Krisztina Vukics, Ferenc Baska, Gábor Szántó, Balázs Krámos, Katalin Domány-Kovács, Krisztina Szondiné Kordás, Mónika Vastag, Ildikó Magdó, Imre Bata","doi":"10.1016/j.ejmech.2024.117069","DOIUrl":null,"url":null,"abstract":"<div><div>The development of a dual V1a/V2 antagonist compound is a complex and challenging task. Conivaptan is up to now the only known V1a/V2 antagonist which was approved for the treatment of euvolemic hyponatremia. Previously, we reported <strong>RGH-122</strong>, a novel selective V1a antagonist compound. Herein, we describe several promising dual antagonist compounds, which are derived from <strong>RGH-122</strong> by using modifications in its tail region. These modifications can result in excellent binding affinity on both V1a and V2 receptors.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"283 ","pages":"Article 117069"},"PeriodicalIF":6.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523424009516","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The development of a dual V1a/V2 antagonist compound is a complex and challenging task. Conivaptan is up to now the only known V1a/V2 antagonist which was approved for the treatment of euvolemic hyponatremia. Previously, we reported RGH-122, a novel selective V1a antagonist compound. Herein, we describe several promising dual antagonist compounds, which are derived from RGH-122 by using modifications in its tail region. These modifications can result in excellent binding affinity on both V1a and V2 receptors.
期刊介绍：
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
